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Relevance of a tCGA-derived 
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Seok-Gu Kang10, Xiaonan Li5,6,7,11,12, Do-Hyun Nam9 & Kam M. Hui1,3,4,8,13
Glioblastoma multiforme (GBM), a deadly cancer, is the most lethal and common malignant brain 
tumor, and the leading cause of death in adult brain tumors. While genomic data continues to rocket, 
clinical application and translation to patient care are lagging behind. Big data now deposited in the 
TCGA network offers a window to generate novel clinical hypotheses. We hypothesized that a TCGA-
derived gene-classifier can be applied across different gene profiling platforms and population groups. 
This gene-classifier validated three robust GBM-subtypes across six different platforms, among 
Caucasian, Korean and Chinese populations: Three Caucasian-predominant TCGA-cohorts (Affymetrix 
U133A = 548, Agilent Custom-Array = 588, RNA-seq = 168), and three Asian-cohorts (Affymetrix 
Human Gene 1.0ST-Array = 61, Illumina = 52, Agilent 4 × 44 K = 60). To understand subtype-relevance 
in patient therapy, we investigated retrospective TCGA patient clinical sets. Subtype-specific patient 
survival outcome was similarly poor and reflected the net result of a mixture of treatment regimens 
with/without surgical resection. As a proof-of-concept, in subtype-specific patient-derived orthotopic 
xenograft (PDOX) mice, Classical-subtype demonstrated no survival difference comparing radiation-
therapy versus temozolomide monotherapies. Though preliminary, a PDOX model of Proneural/Neural-
subtype demonstrated significantly improved survival with temozolomide compared to radiation-
therapy. A larger scale study using this gene-classifier may be useful in clinical outcome prediction and 
patient selection for trials based on subtyping.
Glioblastoma (GBM), a deadly brain cancer, is the most lethal and common malignant brain tumor and the 
leading cause of death in adult brain tumors. Despite the advances in genomics and molecular classification1–8, 
the survival of GBM patients has not improved over the last decade9–11. The median survival of GBM patients is 
less than 16 months despite a multitude of therapies9–11. Standard of care is radiation therapy and temozolomide, 
which gives the best 2-year overall survival of about 25%9–11. While genomic data continues to rocket, clinical 
application and translation to patient care are lagging behind. Big data now deposited in The Cancer Genome 
Atlas (TCGA) network offers a window to generate novel clinical hypotheses. One overarching theme is how 
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genomics can be applied to derive clinically relevant information to improve therapy for patients. We hypothe-
sized that a TCGA-derived gene-classifier can be applied across different gene profiling platforms and population 
groups. Using an enhanced gene expression data set from Caucasian-predominant TCGA-cohorts, we derived 
a subtype gene-classifier and validated our subtype-prediction model on six different platforms over a decade 
(Caucasian-predominant cohorts: Affymetrix U133A = 548, Agilent Custom Array = 588 and RNA-seq = 168 
deposited in TCGA, and additional three Asian-cohorts Affymetrix Human Gene 1.0 ST array = 61; Illumina 
HumanHT-12 v4 Expression BeadChip = 52; Agilent 4 × 44 K Whole Genome Oligo Microarray = 60). This 
provides institutions profiling patient tumors on various platforms with a model to predict GBM-subtypes on 
different patient populations (Caucasian, Korean and Chinese patients). In a therapeutic context, patient sur-
vival curves reflect a net result of a mixture of different treatment regimens, with or without surgical resec-
tion of varying extent. If we are able to dissect the knowledge of a particular GBM-subtype which is more 
temozolomide-responsive or radiotherapy-responsive, this will provide a core treatment stem for testing novel 
agents in combination, targeting at a specific GBM-subtype. As a proof-of-concept, we postulated that survival 
differed by subtypes in context of GBM-relevant therapies, and any difference in treatment response will be 
clearer if we study the individual effects with monotherapy arms of the two most common treatment modalities 
in GBM, radiation therapy versus temozolomide, in a panel of patient-derived orthotopic xenograft mice (PDOX) 
without any surgical resection of tumor (lessening tumor burden) or a mixture of therapies confounding the 
survival data. Our findings from this study, if done on a larger scale, may be useful in clinical outcome prediction 
and patient selection for trials based on subtyping. Our gene-classifier was validated on six different gene profiling 
platforms and relevant among populations of Caucasian, Korean and Chinese patients.
Results
Derivation of a subtype gene-classifier applicable for glioblastoma tumors profiled on multi-
ple platforms among Caucasian, Korean and Chinese populations. Following the original four 
GBM-subtype classification by Verhaak1, several studies12–14 have reported refinement of the classification into 
three GBM-subtypes. In agreement with these studies12–14, we validated three robust GBM-subtypes (Classical, 
Mesenchymal and Proneural/Neural) but individually on six different platforms: TCGA-cohorts deposited over a 
decade (Affymetrix U133A = 548, Agilent Custom Array = 588 and RNA-seq = 168), and three additional Asian-
cohorts (Affymetrix Human Gene 1.0 ST array = 61; Illumina HumanHT-12 v4 Expression BeadChip = 52; 
Agilent 4 × 44 K Whole Genome Oligo Microarray = 60) by consensus clustering15. To curate outlying sam-
ples, we performed silhouette width analysis16 to include only the core samples that were most representative of 
each of the three clusters (TCGA-cohorts core samples: n1 = 496 Affymetrix U133A, n2 = 523 Agilent, n3 = 150 
RNA-seq; Supplemental 1, 2). We demonstrated that the original Verhaak 840-gene-set initially derived through 
a smaller number of 200 GBM samples (assayed on three gene expression platforms integrated into a single 
dataset)1, was unable to robustly cluster the larger TCGA-cohorts now available on different platforms (Fig. 1A; 
Supplemental 1). Through rigorous interrogation using 1500, 1000 and 500-gene-sets comprising of top ranked 
variable genes using maximum median absolute deviation (MAD) score, in systematic genomic simulations by 
Figure 1. Derivation of a glioblastoma-subtype gene-classifier through three different platforms. Caucasian-
predominant cohorts, TCGA: All samples - Affymetrix U133A = 548 (training set), Agilent = 588, RNA-
Seq = 168. (A) Consensus clustering matrix for k = 4 of 548 glioblastoma (GBM) samples (training set) using 
Verhaak’s1 840-gene-set revealed a small, unstable 4th cluster (red box), suggesting the previous 840-gene-set 
comprised of insufficient genes to classify current larger TCGA-cohort (Supplemental 1). (B) Consensus 
clustering matrix for k = 3 of same training set using 500 gene-classifier and silhouette plot identified 496 core 
samples (n1 = 496), Supplemental 2 (k = 2 to k = 10). 500 gene-classifier comprised of top 500 differentially 
expressed genes between patient tumors (548 samples) and normal brain tissues (10 samples) curated 
through rigorous interrogation using 1500, 1000 and 500-gene-sets (Supplemental 2) in systematic genomic 
simulations derived from training set core samples. (C) Only 108 genes overlapped between 500 gene-classifier 
and Verhaak’s1 original 840 genes. (D) Comparison of subtype nomenclature using Vehaak’s1 840-gene-set 
versus 500-gene-set in 189 patient tumors (original Verhaak’s1 cohort) revealed 157/189 (83%) GBM tumors 
matched original Verhaak1 subtype nomenclature. Importantly, 32/189 (17%) patient GBM tumors had subtype 
nomenclature revised.
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consensus hierarchical clustering derived from training set (n1 = 496, Caucasian-predominant), we showed that 
a 500-gene-set was sufficient to recapitulate three GBM-subtypes (Fig. 1B, Supplemental 2) in two Caucasian-
predominant validation sets (n2 = 523 Agilent, n3 = 150 RNA-Seq, TCGA cohorts) and three Asian-cohorts (core 
samples: Asian Cohort 1− n4 = 51 Affymetrix Human Gene 1.0 ST array; Asian Cohort 2 − n5 = 45 Illumina 
HumanHT-12 v4 Expression BeadChip; Asian Cohort 3 − n6 = 59 Agilent 4 × 44 K Whole Genome Oligo 
Microarray, Fig. 2D–F). Consensus hierarchical clustering uses repeated subsampling and clustering to calculate 
the consensus of these repetitions, which is robust relative to sampling variability, and is also the same meth-
odology employed in TCGA-classification of tumor subtypes17 (Broad Institute methodology, Supplemental 2). 
Additionally, consensus hierarchical clustering by default performs 1000 bootstrap iterations which confirms the 
Figure 2. Comparison of Vehaak’s1 840 gene model with 500 gene model and cross-ethnic application of 500 
gene-classifier illustrating subtype predominance among patient populations of Caucasians, Koreans and 
Chinese. (A) Sample sizes of all three TCGA-cohorts: 157 patient tumors overlapped between three cohorts.  
(B) Comparison of consensus hierarchical clustering plots using Vehaak’s1 840-gene-set versus 500 gene-
classifier (k = 3, k = 4) across all TCGA-cohorts: Core samples n1 = 496 Affymetrix U133A, n2 = 523 Agilent, 
n3 = 150 RNA-Seq. Vehaak’s1 840-gene-set produced less distinct clusters compared to 500-gene-set (k = 3). 
A small, unstable 4th cluster (red box) emerged with k = 4. (C) Subtype distribution in 430 Caucasian GBM 
patients with ethnicity data available in training set (n1 = 496). (D–F) Comparison of consensus hierarchical 
clustering plots using Vehaak’s1 840-gene-set versus 500 gene-classifier (k = 3, k = 4) across Asian-cohorts: 
Core samples: n4 = 51 Affymetrix Human Gene 1.0 ST array, n5 = 45 Illumina HumanHT-12 v4 Expression 
BeadChip, n6 = 59 Agilent 4 × 44 K Whole Genome Oligo Microarray. 500 gene-classifier recapitulated three 
GBM subtypes and produced more distinct clusters compared to Vehaak’s1 840-gene-set in two Asian-cohorts 
of Korean descent and one Asian-cohort of Chinese descent. Classical subtype (49%) was the predominant 
subtype in Asian Cohort 1. Classical subtype was less common in Asian Cohort 2, which predominantly 
comprised of older GBM patients (50–70 years old), and in Asian Cohort 3. Proneural/Neural subtype was more 
common in Asian Cohort 2 and 3 compared to Asian Cohort 1.
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robustness of the clustering. The 500-gene-set was curated from the top 500 most variable genes in expression, 
using maximum MAD score, as a robust measure of variability to rank genes with expression values of maximal 
variation across the samples. Only 108 genes were common between Verhaak’s 840-gene-set and the 500-gene-set, 
remaining 392/500 genes were unique (Fig. 1C).
We compared the results of consensus hierarchical clustering using Verhaak’s 840-gene-set and the 500-gene-set 
across all six patient cohorts of GBM tumors profiled on different platforms (Fig. 2B,D–F, Supplemental 1, 
2Ciii,D,E). Clusters formed using Verhaak’s 840-gene-set composed of a small, unstable 4th cluster (k = 4) and less 
clear clusters with k = 3. In contrast, the 500 gene-classifier formed three clear clusters (Fig. 2B).
We mapped the subtype identity of each patient tumor in the TCGA training set (n1 = 496), comparing the 
GBM-subtype nomenclature defined by Verhaak’s 840-gene-set and our 500 gene-classifier (Supplemental 3A). 
Our analyses demonstrated that the original Proneural and Neural subgroups defined by Verhaak’s 840 gene-set, 
now formed a single cluster (Proneural/Neural subtype) using the 500 gene-classifier (Supplemental 3A). The 
remaining two clusters matched the subgroups defined by Verhaak’s GBM-subtype nomenclature of Classical 
subtype and Mesenchymal subtype (Supplemental 3A). Subtype-specific genes derived from each of the three 
GBM-subtypes defined by 500 gene-classifier, were enriched in different signaling and metabolic pathways (p 
value <0.05 by Fisher Exact Test, Fold-change |FC| > 2) by Ingenuity pathway analyses (Supplemental 3B, 4). As 
a validation, we used a gene-set comprising of 500 randomly selected genes to perform a consensus clustering 
analyses of the TCGA training set, the three clusters could not be created, supporting that the 500 gene-classifier 
was essential to construct the three GBM-subtypes (Supplemental 3C). Seventeen percent (32/189 from Verhaak’s 
cohort) of GBM tumors had original subtype nomenclature reclassified by 500 gene-classifier (Fig. 1D). Of the 
tumors which had subtype reclassified, majority (23/32, 71.9%) were revised to Mesenchymal subtype, from 
Proneural/Neural (37.5%) and Classical subtype (34.4%).
Of all three TCGA cohorts, 157 patient tumors overlapped in all cohorts (Fig. 2A), of which 119 were core 
samples. We compared the 500 gene-classifier on these 119 core samples across all 3 TCGA platforms (Affymetrix 
U133A, Agilent, RNA-seq), only 1 tumor was mismatched in subtype identity across all three platforms. For 
the remaining tumors (118/119), subtype identity agreed across three platforms (78.8%) and two platforms 
(21.2%). The highest agreement was between Agilent and RNA-seq platforms (88.2% agreement), followed by 
Affymetrix U133A and Agilent platforms (86.5% agreement), and Affymetrix U133A and RNA-seq platforms 
(80.7% agreement).
Additionally, we tested another independent 150-gene-set reported by Wang12 by consensus hierarchical clus-
tering on the TCGA training set (n1 = 496). The clustering effect was less distinct using Wang’s 150-gene-set 
(Supplemental 2F) compared to the 500-gene-set (Fig. 1B). Only 21 genes were common between Wang’s 
150-gene-set and our 500-gene-set (Supplemental 2F).
Tumor subtype patterns among populations of Caucasians and Asians. Caucasians appeared to 
have a predominant Proneural/Neural subtype (41.2%) in the TCGA training set (Caucasian = 430 patients with 
assessable ethnicity data, Fig. 2C). Among the three Asian-cohorts surveyed, this subtype was less predominant 
in Asian Cohort 1 (Koreans, 17.6%, Fig. 2D), more common in Asian Cohort 2 (Koreans, 33.3%, Fig. 3E) and 
Asian Cohort 3 (Chinese, 37.3%, Fig. 2F). In contrast, Classical subtype appeared to be the more predominant 
subtype in Asian Cohort 1, contributing up to 49% (Koreans, Fig. 2D), less common in Asian Cohort 2 (Koreans, 
28.9%, Fig. 2E) and Asian Cohort 3 (Chinese, 23.7%, Fig. 2F). This subtype was less common among Caucasians 
in the TCGA training set (21.2%, Fig. 2D). Mesenchymal subtype appeared more consistent in proportion among 
all cohorts surveyed (TCGA training set, 37.7% and Asian Cohorts 1–3 ranging 33.3%, 37.8%, 39% respectively, 
Fig. 2). It is important to note that the demographics of each of the Asian-cohorts vary and we did not have the 
large-scale resource to interpret the findings in conjunction with multi-dimensional genomics data. However, 
these larger Asian-cohorts were possibly a more accurate representation of the subtype distribution among Asian 
GBMs compared to the smaller Asian TCGA cohort (n = 13, Supplemental 3D). It should be highlighted that the 
sample size for the Caucasian-predominant TCGA-cohort was very much larger. This was a descriptive obser-
vation, and no conclusive findings can be made as other correlates such as mutational status were not analyzed, 
populations were demographically distinct and the Asian-cohorts were much smaller than TCGA-cohorts.
Treatment response in preclinical models of each GBM subtype. Most GBM prediction models 
reported18–22 were prognostic-based. However, almost all GBM patients die, with the best 2-year overall survival 
of about 25%9–11, which limited the clinical utility of prognostic-prediction models. Further, in these prognostic 
models, patients had received a heterogenous mixture of treatment regimens, which posed additional challenges for 
interpretation and translation into clinical application19,21,22. We postulated that survival differed by subtypes in 
response to individual effects of each single-agent therapy, for the two treatment modalities used in the standard 
of care for GBM – temozolomide and radiation therapy. In the clinical context, patients had mostly received a 
heterogenous mixture or combination of treatment regimens with or without surgical resection of varying extent. 
Using large retrospective clinical sets from TCGA with assessable outcome data for good statistical power, we 
stratified these patients into three GBM-subtypes using the 500 gene-classifier. Subtype-specific patient survival 
outcome was similarly poor and reflected the net result of a mixture of treatment regimens with or without surgi-
cal resection of varying extent (Fig. 3A). Next, we questioned if PDOX mice bearing tumor xenografts of each of 
the three GBM-subtypes, differed in treatment response to individual arms of radiation therapy versus temozolo-
mide, in context of GBM-relevant therapies. This allows the treatment response of a single tumor subtype from 
each patient, to be studied in three different settings of no treatment, temozolomide monotherapy and radiation 
monotherapy, to investigate if there exist temozolomide-responsive or radiotherapy-responsive subtypes, without 
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Figure 3. Treatment response to individual effects of temozolomide versus radiation therapy among patient-
derived orthotopic mouse models of three glioblastoma subtypes. (A) Survival data from patients who received a 
heterogenous mixture of treatment regimens from the two largest TCGA cohorts (n1 = 496, n2 = 523) illustrated a 
better overall survival outcome for Proneural/Neural (previously defined by IDH-mutant and younger patient age, 
which were reported to have better prognosis4) versus Mesenchymal subtype (p < 0.05). Subtype-specific patient 
survival outcome was overall poor and reflected the net result of a mixture of treatment regimens with/without 
surgical resection. Patient survival pattern paralleled some similarity to treatment naïve patient-derived orthotopic 
xenograft (PDOX) mice which received no treatment, although as expected mice survival was remarkably shorter 
than patient survival. (B) As a proof-of-concept, in subtype-specific PDOX mice, Classical-subtype which was well-
represented by 10 PDOX models in our cohort, demonstrated no survival difference comparing individual effects of 
radiation therapy versus temozolomide (p = 0.71). Though preliminary, a PDOX model of Proneural/Neural-subtype 
demonstrated survival benefit temozolomide (n = 10, p < 0.001) compared to untreated mice (n = 15), while no 
survival benefit was observed with radiation therapy (n = 10, p = 0.06) compared to untreated mice (n = 15).
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surgical resection (lessening tumor burden) of these tumors in mice or a mixture of therapies confounding the 
interpretation of survival data.
As a proof-of-concept, we showed in a large cohort of 321 PDOX GBM mouse models derived from 13 
treatment-naïve patient GBM tumors from Asian Cohort 1 (Fig. 3B), that Classical subtype demonstrated no sur-
vival difference comparing radiation therapy with temozolomide treatment (p = 0.71). Classical subtype PDOX 
models displayed similar survival advantage with radiation therapy (p < 0.001) or temozolomide (p < 0.001) 
compared with untreated mice (Fig. 3B). We have a larger representation of Classical subtype PDOX models (No 
Treatment: 10 patient models, Treatment 1-Temozolomide: 9 patient models, Treatment 2-Radiation Therapy: 
7 patient models), compared to the other two subtypes, which may be partly contributed by the larger propor-
tion of Classical subtype tumors in Asian-cohort 1 (Fig. 2D) compared to Caucasian-cohorts (Fig. 2A). Though 
preliminary, among PDOX mice implanted with Proneural/Neural GBM (PDOX Model 7, Supplemental 5) 
from one patient tumor model, we observed significant survival difference between temozolomide-treated and 
radiation-therapy-treated mice (Fig. 3B). Treated mice from PDOX Model 7 demonstrated significant survival 
benefit with temozolomide (n = 10, p < 0.001) compared to untreated mice (n = 15), while no survival benefit 
was observed with radiation therapy (n = 10, p = 0.06) compared to untreated mice (n = 15, Fig. 3B). In two 
Mesenchymal subtype PDOX models (PDOX Model 9 and 10), temozolomide treatment (n = 14) did not confer 
significant survival benefit in mice compared to untreated mice (p = 0.05, n = 30, Fig. 3B).
It was unclear if Classical subtype GBM tumors have a selective growth advantage and tumor take-rate in 
PDOX models compared to other subtypes, and we were limited by the smaller number of Proneural/Neural and 
Mesenchymal subtype PDOX models. But among these few PDOX models, though preliminary, temozolomide 
appeared to confer a significant and selective survival advantage to the PDOX model of Proneural/Neural sub-
type compared to radiation therapy (p < 0.001, Fig. 3B), while for two PDOX models of Mesenchymal subtype, 
treatment with temozolomide did not give any significant benefit compared to untreated mice (p = 0.05, Fig. 3B). 
Treatment-naïve mice of each subtype also exhibited different survival characteristics (p < 0.001). The number of 
models in each subtype was dependent on the patients who presented consecutively during the period of PDOX 
creation, available patient tissue samples for injection and post-treatment mouse survival data pooled from vari-
ous studies23,24 involving this panel of PDOX models from Asian Cohort 1, and therefore not equally distributed 
among subtypes. We acknowledge this limitation, but our goal in this study was to capture the most compre-
hensive cohort of mice with patient tumors injected from the Asian validation cohort. Each of the 13 patient 
tumors had an average of 11, 8 and 10 mice (replicates) per model respectively in No Treatment, Treatment 1 
(Temozolomide) and Treatment 2 (Radiation Therapy) groups (Supplemental 5), and the survival curves (Fig. 3A) 
reflected a collection of all the mice within each subtype. This study was not designed with a fixed number of mice 
from all three subtypes to undergo different therapies, therefore for the group of mice that received radiation 
therapy, there were only two subtypes available. As the data was extracted from post-treatment mouse survival 
data pooled from various studies23,24 involving this panel of PDOX from Asian Cohort 1, there were no animals 
treated with combined temozolomide-radiation therapy in these studies, hence this data was not available to be 
included in our current survival analyses. However, the observed differences of the treatment response in mice, 
highlighted a gap to be addressed in larger scale studies to investigate the subtype-specific treatment effects for 
appropriate patient selection in subtype-based therapy.
Recent emerging evidence supports the importance of patient selection based on subtypes in clinical trials and 
therapeutic drug development25. Survival data from patients who received a heterogenous mixture of treatment 
regimens (chemotherapy or radiation therapy or combination of chemotherapy with radiation therapy, with or 
without surgical resection), from the two largest TCGA cohorts (Affymetrix n1 = 496, Agilent n2 = 523, Fig. 3A) 
illustrated a better overall survival outcome for Proneural/Neural (previously defined by IDH-mutant and 
younger patient age, which were reported to have better prognosis4) versus Mesenchymal GBM (p < 0.05). The 
patient survival pattern paralleled some similarity to treatment naïve PDOX mice which received no treatment, 
although as expected mice survival was remarkably shorter than patient survival. Most survival data from GBM 
patients19,21,22, including our Asian cohorts, reflected the outcome of a heterogenous mixture of treatment regimens 
and different extent of surgical resection of tumor bulk, which posed further challenges to meaningfully inter-
pret patient data for subtype-specific responses to individual effects of temozolomide versus radiation therapy, 
in context of GBM-relevant therapy. Therefore, we sought post-treatment mouse survival data to provide some 
biological evidence for new clinical insights, investigating the individual effects of each single-agent therapy, for 
the two common treatment modalities in the standard of care in GBM.
Discussion
Here, we present clinically relevant biological data in a proof-of-concept study investigating TCGA-cohorts to 
derive a gene-classifier that can be applied across different gene profiling platforms and population groups. Our 
findings from this study, if done on a larger scale, may be useful in clinical outcome prediction and patient selec-
tion for trials based on subtyping. We validated three GBM-subtypes using our gene-classifier on six different 
platforms among Caucasian, Korean and Chinese populations. This will provide institutions profiling patient 
tumors on various platforms internationally, with a model to predict GBM-subtypes in adults. We did not find 
this gene-classifier useful in subtyping pediatric GBMs (Supplemental 3F), which previously26 have been reported 
to be a different disease from adults.
The rapidly emerging field of epigenomics and the explosion of large-scale genomics have dissected GBM 
tumors into complex molecular subgroups7 and provided insights on GBMs across age groups26. This study nei-
ther attempted nor was designed to reconcile all levels of genomic data available for GBM27–30, but rather to har-
monize and derive a robust subtype-prediction model, which can be relevant to Caucasian, Korean and Chinese 
patient populations of adult GBM, independent of gene profiling platforms. To address the ground truth of the 
subtype of each patient tumor correlating with multi-dimensional genomic data such as MGMT methylation 
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status9,31 and IDH1/2 mutations4, and more recently, TERT and ATRX mutations32, will require larger resources 
and scale of study. We acknowledge this limitation. Future studies incorporating these elements into the 500 
gene-classifier to apply to the issues of ethnicity-based analyses will be useful to enrich the current classification 
scheme. However, our finding of three transcriptomic GBM subtypes is consistent with other post-Verhaak’s stud-
ies that reported three GBM subtypes at the proteomic level13, and another study that described three GBM sub-
types using integrated data from gene expression clustering with Verhaak’s 840 gene and methylation data14. The 
study reporting integrated subtypes14 found four dispersed transcriptomic clusters using Verhaak’s 840 gene-set, 
which is consistent with our findings with Verhaak’s gene set. The relevance of molecular cancer signatures across 
ethnic groups remains an under-investigated field - whether cancer signatures derived from Caucasian patients 
can be applied on other large ethnic groups such as Asians, contributing to a majority 60% of the world’s ~7 
billion population. While high throughput genomic data rapidly accumulates, the gap widens between genomic 
science and clinical translation of genomic information to patient care.
Nonetheless, it is difficult to meaningfully interpret Asian GBM-subtype distribution based on the small 
sample size of Asians in TCGA training set (n = 13). We therefore sought additional larger Asian-cohorts (core 
samples: n4 = 51, n5 = 45, n6 = 59) to validate our gene-classifier. Limitations include variation of demographics 
among the Asian-cohorts vary and lack of large-scale multi-dimensional genomics resource. Here, we present 
a descriptive observation, since other correlates such as mutational status were not analyzed, populations were 
demographically distinct and the Asian-cohorts were much smaller than TCGA-cohorts. Among the cohorts 
surveyed, Caucasian-predominant TCGA training set was Proneural/Neural subtype predominant (41.2%). This 
subtype was less common in Asian Cohort 1 (Koreans, 17.6%), more common in Asian Cohort 2 (Koreans, 
33.3%) and Asian Cohort 3 (Chinese, 37.3%). Classical subtype appeared to be the more predominant subtype in 
Asian Cohort 1 (Koreans, 49%), less common in Asian Cohort 2 (Koreans, 28.9%) and Asian Cohort 3 (Chinese, 
23.7%). This subtype was less common among Caucasians in the TCGA training set (21.2%). Mesenchymal sub-
type appeared more consistent in proportion among all cohorts surveyed. We found another cohort of 88 Chinese 
GBM patients (RNA-seq), comprising of Mesenchymal subtype (41%), Classical subtype (36%), and Proneural/
Neural subtype (23%)33,34.
To our knowledge, while there are studies comparing glioma types of different WHO grading among ethnic pop-
ulations (lower survival among non-Hispanic whites for GBM)35, there are no studies investigating GBM-subtype 
distribution among ethnic groups. Incidence of GBM is higher in the male gender and among ethnic groups of 
White and non-Hispanics36. The incidence rate of GBM among Blacks, Asians/Pacific Islanders, and American 
Indians/Alaskan Natives was substantially lower compared to non-Hispanic whites37. Our findings represent an 
early effort to survey and describe GBM-subtype distribution between patient populations of two ethnic groups of 
Caucasians and Asians (2 Korean-cohorts and 1 Chinese-cohort). We report a TCGA-derived subtype-prediction 
model which can be useful for institutions profiling patient tumors on various platforms among populations of 
Caucasian, Korean and Chinese patients to predict GBM-subtypes. This approach can be applied to other tumor 
types with big data deposited in TCGA, investigating TCGA-cohorts to understand correlation with Asian ethnicity. 
Larger scale studies might be useful in clinical outcome prediction and patient selection for trials based on subtyping 
for other major cancers. Our gene-classifier is validated among Caucasian and Asian populations and can be relevant 
in understanding the subtype patterns among ethnic populations if applied on a larger scale. Subtype patterns may 
be relevant for translating subtype-specific trials across international patient populations.
In the clinical context, patients had mostly received a heterogenous mixture or combination treatment reg-
imens with or without surgical resection of varying extent. Using large retrospective clinical sets from TCGA 
with assessable outcome data for good statistical power, subtype-specific patient survival outcome was similarly 
poor and reflected the net result of a mixture of treatment regimens with or without surgical resection of vary-
ing extent. As a proof-of-concept, in subtype-specific PDOX mice, Classical subtype demonstrated no survival 
difference comparing the individual effects of radiation therapy versus temozolomide monotherapies. We also 
observed that temozolomide did not confer significant survival benefit in two Mesenchymal subtype PDOX mod-
els, compared to untreated mice. Though preliminary, a PDOX model of Proneural/Neural subtype demonstrated 
significantly improved survival with temozolomide compared to radiation therapy. Our approach is clinically 
relevant. It compares the individual effects of temozolomide versus radiation therapy, the two most common 
treatment modalities in GBM, among PDOX models without surgical resection (lessening tumor burden) of these 
tumors in mice or a mixture of therapies confounding the interpretation of survival data. It allows the treatment 
response of a single tumor subtype from each patient, to be studied in three different settings of no treatment, 
temozolomide monotherapy and radiation monotherapy, to investigate if there exist temozolomide-responsive or 
radiotherapy-responsive subtypes. Our study was limited in design as the data was extracted from post-treatment 
mouse survival data pooled from various studies23,24 involving this panel of PDOX from Asian Cohort 1, and 
fewer PDOX models on Proneural/Nerual and Mesenchymal subtypes. However, our Classical PDOX models 
were well-represented, and our sample size of 13 PDOX models from Asian Cohort 1 was appropriately-sized for 
the funding and manpower resources allocated for each of these PDOX projects in the PDOX modelling field. 
Creation of PDOX models is a lengthy and costly process. PDOX models are still the preferred cancer model over 
culture-based spheroids or slice cultures. In 2016, the US National Cancer Institute (NCI) has decided to stop 
screening most drugs using the NCI-60, its panel of 60 human cancer cell lines grown in culture, after more than 
25 years of heavy use by worldwide researchers, and is developing PDOX models that better mimic the human 
counterpart. Specifically, a targeted approach of testing drugs with subtype-specific models, which we illustrate 
here, but with extended collaborations to various international groups studying GBMs, and each research group 
with a defined focus on different subtype-specific models, may be a cost- and time-effective approach to team 
science using PDOX models, without compromising the value of data we can derive from PDOX models. Our 
observations highlight a gap to be addressed in larger scale PDOX studies to prospectively investigate the differ-
ential treatment response for subtype-based GBM patient selection.
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Methods
Patients and tumor samples. GBMs and normal brain tissue samples were obtained from The Cancer 
Genome Atlas (TCGA) Research Network with data available on three different platforms RNA-seq, Affymetrix 
HT-HG-U133A arrays and custom designed Agilent arrays. We downloaded open access TCGA Level-3 data 
on 4 Feb 2015 using the TCGA data portal. Level-3 data has been already normalized for downstream analyses. 
We have chosen genes that were common on all 3 platforms for the analyses. We used 548 GBMs and 10 normal 
samples (Affymetrix HT-HGU133A array) and 588 GBMs and 10 normal samples (Agilent array) and 168 GBMs 
and 5 normal samples (RNA-seq) to identify differentially expressed genes (DEGs) between GBMs and normal 
brain tissue samples. Figure 2 and Supplemental 3D summarized the patient demographic information on age 
of diagnosis and ethnicity with the molecular subtype. We used 548 GBMs from Affymetrix HT-HGU133A as a 
training set for constructing consensus average linkage hierarchical clustering and we used other two platform 
datasets (588 tumors on Agilent and 168 tumors on RNA-seq) as validation sets. A total of 595 non-overlapping 
tumor samples were found in all 3 GBM cohorts in TCGA (Affymetrix HT-HGU133A, Agilent and RNA-seq). 
Asian Cohort 1 of 61 adult GBM patients was derived by combining a previously published set of 58 patients 
(GSE42670)23 with 3 additional new patients from the same single institution. Asian Cohort 2 comprised of 
52 adult GBM patients from Yonsei University Hospital, normalized gene expression values were provided for 
Verhaak’s1 840 genes and 500 genes in our gene-classifier (Gene List A). Asian Cohort 3 comprised of 60 adult 
GBM patients from a previously published data set (GSE74187) Tian Tan Hospital, China38. Gene expression 
profiling experiments for Asian Cohort 1 were conducted using Affymetrix Human Gene 1.0 ST array according 
to manufacturer’s protocol23. Gene expression profiling experiments for Asian Cohort 2 were conducted using 
Illumina HumanHT-12 v4 Expression BeadChip according to manufacturer’s protocol. Gene expression profil-
ing experiments for Asian Cohort 3 were conducted using Agilent 4 × 44 K Whole Genome Oligo Microarray 
according to manufacturer’s protocol38. Pediatric cohort of 25 patients is obtained from GSE1957826, the gene 
expression profiling experiments were performed on Affymetrix Human Genome U133 Plus 2.0 Array (HG-
U133 Plus 2). TCGA training set comprised of 475 patients with identifiable ethnicity (core samples), of which 
430 were Caucasians, 13 Asians, and 32 African-Americans (Supplemental 3D). This study comprised of analyses 
of retrospective data-sets deposited in the public domain, and ethics approval was obtained from Centralized 
Institutional Review Board at SingHealth. The other relevant ethics approval for each of these retrospective data 
sets can be found in the respective studies cited. Asian Cohort 2 study was approved by the institutional review 
board of Severance Hospital, Yonsei University College of Medicine and conformed to the requirements of the 
Declaration of Helsinki. These patients provided written informed consent.
Data filtering for identification of DEGs. Several filters were applied to identify most tumour specific 
relevant genes for clustering. We identified differentially expressed genes between GBMs and normal brain tissue 
samples in all three datasets separately using ANOVA comparisons. A cut-off of P < 0.05, Q < 0.05 and |FC| > 2 
were used which identified 2723 differentially expressed genes in Affymetrix HT-HGU133A dataset and 3284 
differentially expressed genes in Agilent array and 6753 differentially expressed genes in RNA-seq dataset. We 
overlapped three sets of differentially expressed genes and identified a final set of 1500 genes (Gene List B). 
The second filter was applied using median absolute deviation score (MAD score) higher than 0.5, which elimi-
nated genes with low variability across patients. Three different simulations were performed using differentially 
expressed genes that were ranked based on the MAD score. Top 1500, 1000 and 500 genes were selected based on 
the high MAD score and was used for consensus hierarchical clustering (Supplemental 2). The clustering results 
were compared based on these three gene sets. The minimal gene set of 500 genes was sufficient for identifying 
GBM subtypes.
Consensus hierarchical clustering. Consensus hierarchical clustering is a resampling-based clustering 
algorithm that provides a way to represent the clustering consensus across multiple runs of a clustering algo-
rithm and helps to assess the stability of the discovered clusters. We used hierarchical clustering with agglomer-
ative average linkage, as our basis for consensus clustering, to detect robust clusters15. The distance metric was 
1-(Pearson’s correlation coefficient) and the procedure was run over 1000 iterations and a subsampling ratio of 
0.8 was used to cluster the training cohort of 548 GBM samples with 500 reliably-expressed gene set identified 
based on various filtering.
Identification of gene expression-based subtypes. We used consensus average linkage hierarchical 
clustering15 approach to identify subgroups based on the 500 reliably-expressed genes identified using the above 
filter. We used Pearson’s correlation as the distance metric and 0.8 as subsampling ratio using the training set of 
548 GBM’s. Over 1000 iterations were performed to identify the stable clusters using the top 500 genes. Silhouette 
width analysis using (R-package: Silhouette) was performed to identify the core samples that were most repre-
sentative of the clusters16. ANOVA comparisons between all three subgroups both pairwise and in combination 
were performed to identify subtype specific genes which were highly expressed in specific subtype.
Statistical analyses. Statistical Analysis was performed using Partek Genomics Suite software, version 6.6 
Copyright ©; 2016 Partek Inc., St. Louis, MO, USA. Kaplan-Meier Survival Analysis was performed using PASW 
Statistics 18, Release 18.0.0 (July 30, 2009).
Identification of subtype specific pathways. We used Ingenuity Pathway Analysis (IPA) to identify 
significant pathways (Supplemental 4, 3B) associated with the subtype specific genes (Gene List C). The top ten 
canonical pathways were generated in IPA and the significant pathways (p < 0.05; calculated by Fisher’s exact test) 
were chosen for each subgroup to identify signaling pathways that are specific to each subgroups.
9Scientific RepoRts |          (2019) 9:7442  | https://doi.org/10.1038/s41598-019-43173-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
Orthotopic xenograft animal model. Animal experiments were approved by the Institutional Review 
Board and conducted in accordance with the “National Institutes of Health Guide for the Care and Use of 
Laboratory Animals” (NIH publication). Tumors were classified as GBM based on WHO criteria after review 
by pathologists. Parts of the surgical samples were enzymatically dissociated into single cells, following the pro-
cedures previously reported23. Dissociated GBM cells were cultured in neurobasal media with N2 and B27 sup-
plements (0.5X each; Invitrogen) and human recombinant bFGF and EGF (25 ng/ml each; R&D Systems) (NBE 
condition). Acutely dissociated GBM cells were stereotactically (2 mm left and 1 mm anterior to the bregma, 
2 mm deep from the dura) injected into the brains of immune-compromised NOD/SCID Il2rg−/− (NOG) mice 
within 12 hours after surgery (2.5 × 104–1.0 × 105 cells in 10 ml HBSS for each mice, n = 4–19 for each sample). 
Mice with the reduction of the total body weight (>20%) were sacrificed, and brains were processed for paraffin 
or frozen section.
Whole-brain In Vivo irradiation and temozolomide chemotherapy. Orthotopic xenograft tum-
ors were made as described above, using primarily cultured GBM cells that had short term in vitro culture in 
the NBE condition (in vitro passage <6, 2.0 × 105 cells for each animal). Treatments were started at the half of 
the median survival length of the orthotopic xenograft animal models. The reduction of the total body weight 
(>20%) was regarded as mortality. Whole brain 2 Gy X-irradiations were applied daily for 5 days (total 10 Gy) 
using a blood irradiator (IBL-437C, CIS-US). Mouse bodies were shielded with a custom-made lead shield device. 
Temozolomide (65 mg/kg) was orally administrated daily.
Data Availability
The Cancer Genome Atlas (TCGA) Research Network; Accession Codes- GSE42670, GSE19578, GSE74187.
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